HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
MEP regimen
a chemotherapy regimen consisting of above Cisplatin, Epirubicin & Mitomycin; used for treatment of carcinoma of unknown primary origin
Also Known As:
ME cisplatin
Networked:
2
relevant articles (
0
outcomes,
0
trials/studies)
Therapy Context: Research Results
Therapeutics: 1158551
Drug Therapy: 293145
Combination Drug Therapy: 12066
Antineoplastic Combined Chemotherapy Protocols: 35
MEP regimen: 2
Antineoplastic Protocols: 55
Antineoplastic Combined Chemotherapy Protocols: 35
MEP regimen: 2
Clinical Protocols
Antineoplastic Protocols: 55
Antineoplastic Combined Chemotherapy Protocols: 35
MEP regimen: 2
Inorganic Chemicals: 9
Platinum Compounds: 758
Cisplatin: 46373
MEP regimen: 2
Nitrogen Compounds: 67
Cisplatin: 46373
MEP regimen: 2
Chlorine Compounds: 8
Cisplatin: 46373
MEP regimen: 2
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
Epirubicin: 3820
MEP regimen: 2
Quinones: 434
Indolequinones: 12
Mitomycins: 11
Mitomycin: 7989
MEP regimen: 2
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
Epirubicin: 3820
MEP regimen: 2
Carbohydrates: 22023
Glycosides: 2119
Aminoglycosides: 5131
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
Epirubicin: 3820
MEP regimen: 2
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azirines
Mitomycins: 11
Mitomycin: 7989
MEP regimen: 2
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Indoles: 200
Indolequinones: 12
Mitomycins: 11
Mitomycin: 7989
MEP regimen: 2
Related Diseases
1.
Neoplasms (Cancer)
10/01/1988 - "
The results with the MEP regimen are promising for the advanced, metastatic urothelial cancer.
"
10/01/1988 - "
A higher response rate (85.7%) was obtained by the MEP regimen; a complete response in 2, who had intravesical and nodal (N2, N4) cancer, and a partial response in 4 patients, 1 had intravesical cancer, 1 had nodal (N2) and intravesical cancer and 2 had nodal or lung metastasis of excised renal pelvic cancer.
"
01/01/1994 - "
Combination chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC regimen) or with methotrexate, etoposide and cisplatin (MEP regimen) was administered to 32 patients with advanced measurable uroepithelial cancers.
"
2.
Pelvic Neoplasms
10/01/1988 - "
A higher response rate (85.7%) was obtained by the MEP regimen; a complete response in 2, who had intravesical and nodal (N2, N4) cancer, and a partial response in 4 patients, 1 had intravesical cancer, 1 had nodal (N2) and intravesical cancer and 2 had nodal or lung metastasis of excised renal pelvic cancer.
"
3.
Neoplasm Metastasis (Metastasis)
10/01/1988 - "
A higher response rate (85.7%) was obtained by the MEP regimen; a complete response in 2, who had intravesical and nodal (N2, N4) cancer, and a partial response in 4 patients, 1 had intravesical cancer, 1 had nodal (N2) and intravesical cancer and 2 had nodal or lung metastasis of excised renal pelvic cancer.
"
Related Drugs and Biologics
1.
Vinblastine (Vinblastine Sulfate)
2.
Methotrexate (Mexate)
3.
Etoposide (VP 16)
4.
Doxorubicin (Adriamycin)
5.
Cisplatin (Platino)
Related Therapies and Procedures
1.
Combination Drug Therapy (Combination Chemotherapy)
2.
M-VAC protocol